Please login to the form below

Not currently logged in
Email:
Password:

Bruce Peacock joins Dicerna from Ophthotech

He is appointed to its board of directors and audit committee

edit-Bruce-Peacock_2014US-based biopharma company Dicerna Pharmaceuticals has appointed Bruce Peacock to its board of directors and audit committee.

He joins from Ophthotech where he served since 2010, most recently as its chief financial and business officer and prior to that, his previous roles include serving as chief operating officer of Cephalon and chief financial officer of Centocor.

Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Douglas Fambrough, CEO at Dicerna, said: “Bruce Peacock is a recognised leader in the biotech industry. With an impressive list of accomplishments in operations, management and business development, Bruce will be a terrific addition to our board.”

22nd September 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics